The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Crixivan     (2S)-1-[(2S,4S)-2-hydroxy-4- [[(1R,2R)-2...

Synonyms: indinavir, Compound J, CHEMBL115, Crixivan (TM), SureCN6317, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of indinavir


Psychiatry related information on indinavir


High impact information on indinavir


Chemical compound and disease context of indinavir

  • PATIENTS: 489 patients receiving indinavir, zidovudine, and lamivudine who had 1) a CD4 count of 0.200 x 10(9) cells/L or less after 8 or more weeks of study therapy and 2) plasma HIV-1 RNA measurements obtained at baseline and week 8 [14].
  • Whereas saquinavir also competitively inhibits UGT activity, this drug has not been associated with hyperbilirubinemia, most likely because of the higher K(I) (360 microM) and substantially lower therapeutic levels as compared with indinavir [15].
  • RESULTS: At week 48, the proportion of subjects in the indinavir, saquinavir, ritonavir, nelfinavir and amprenavir groups with plasma HIV-1 RNA < or = 400 copies/ml was 53, 50, 50, 41 and 56%, respectively, and the proportion with HIV-1 RNA < or = 50 copies/ml was 47, 56, 50, 47, and 44%, respectively (by intent-to-treat analysis) [16].
  • DESIGN: Prospective study including 58 treatment-naive subjects who commenced indinavir or nelfinavir and two nucleosides during primary (PHI; n = 28) or chronic HIV-1 infection (CHI; n = 30) [17].
  • Short-term treatment with indinavir fails to reduce the glucose requirement in a patient with malignant insulinoma [18].

Biological context of indinavir

  • A reduction in indinavir exposure of this magnitude could lead to the development of drug resistance and treatment failure [19].
  • L-735,524 is a potent inhibitor of virus replication in cell culture and inhibits the protease-mediated cleavage of the viral precursor polyproteins that results in the production of noninfectious progeny viral particles [20].
  • OBJECTIVE: To determine intracellular concentrations of indinavir (IDV) and investigate the relationship between plasma and intracellular IDV pharmacokinetics in HIV-infected patients [21].
  • The median (interquartile ranges) for indinavir AUC, Cmax and Cmin were 18.1 (15.3-23.8) mg/l x h, 4.1 (3.6-4.8) mg/l and 0.17 (0.12-0.30) mg/l, respectively [22].
  • All PIs, except indinavir, were cytotoxic and inhibited adipogenesis, increased lipolysis and impaired preadipocyte protein synthesis [23].

Anatomical context of indinavir


Associations of indinavir with other chemical compounds


Gene context of indinavir


Analytical, diagnostic and therapeutic context of indinavir

  • MAIN OUTCOME MEASURES: At virologic failure (S1 sample) and 6 weeks later (S2 sample), assessment of protease and reverse transcriptase gene mutations, plasma indinavir level, and degree of viral load rebound; pill count during induction and maintenance periods [38].
  • Mean random plasma indinavir concentrations in the 2 groups with rebound were similar to those of a control group with sustained viral suppression, although levels below 50 ng/mL were more frequent in the triple-drug group than in the control group (P = .03) [39].
  • Indinavir concentrations in hair from patients receiving highly active antiretroviral therapy [40].
  • The mean body-mass index of the groups was similar, and patients in the two indinavir groups did not gain a significant amount of weight after starting the drug [26].
  • Mass spectrometry and HPLC confirmed that these crystals were composed of indinavir [27].


  1. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. Gulick, R.M., Mellors, J.W., Havlir, D., Eron, J.J., Gonzalez, C., McMahon, D., Richman, D.D., Valentine, F.T., Jonas, L., Meibohm, A., Emini, E.A., Chodakewitz, J.A. N. Engl. J. Med. (1997) [Pubmed]
  2. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. Staszewski, S., Morales-Ramirez, J., Tashima, K.T., Rachlis, A., Skiest, D., Stanford, J., Stryker, R., Johnson, P., Labriola, D.F., Farina, D., Manion, D.J., Ruiz, N.M. N. Engl. J. Med. (1999) [Pubmed]
  3. Paronychia and pyogenic granuloma of the great toes in patients treated with indinavir. Bouscarat, F., Bouchard, C., Bouhour, D. N. Engl. J. Med. (1998) [Pubmed]
  4. Alopecia associated with indinavir therapy. Bouscarat, F., Prevot, M.H., Matheron, S. N. Engl. J. Med. (1999) [Pubmed]
  5. Ergotism related to concurrent administration of ergotamine tartrate and indinavir. Rosenthal, E., Sala, F., Chichmanian, R.M., Batt, M., Cassuto, J.P. JAMA (1999) [Pubmed]
  6. Indinavir: a review of its use in the management of HIV infection. Plosker, G.L., Noble, S. Drugs (1999) [Pubmed]
  7. Extrapyramidal symptoms with ritonavir/indinavir plus risperidone. Kelly, D.V., Béïque, L.C., Bowmer, M.I. The Annals of pharmacotherapy. (2002) [Pubmed]
  8. Case report. Intestinal infarction due to vascular catastrophe in an HIV-infected patient. Wang, L., Molina, C.P., Rajaraman, S. The AIDS reader. (2000) [Pubmed]
  9. Normalisation of cerebrospinal fluid biomarkers parallels improvement of neurological symptoms following HAART in HIV dementia - case report. Andersson, L.M., Hagberg, L., Rosengren, L., Fuchs, D., Blennow, K., Gissl??n, M. BMC Infect. Dis. (2006) [Pubmed]
  10. Images in clinical medicine. Indinavir crystalluria. Tsao, J.W., Kogan, S.C. N. Engl. J. Med. (1999) [Pubmed]
  11. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. Hammer, S.M., Squires, K.E., Hughes, M.D., Grimes, J.M., Demeter, L.M., Currier, J.S., Eron, J.J., Feinberg, J.E., Balfour, H.H., Deyton, L.R., Chodakewitz, J.A., Fischl, M.A. N. Engl. J. Med. (1997) [Pubmed]
  12. Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits. Flexner, C. Annu. Rev. Pharmacol. Toxicol. (2000) [Pubmed]
  13. The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. Wang, M.W., Wei, S., Faccio, R., Takeshita, S., Tebas, P., Powderly, W.G., Teitelbaum, S.L., Ross, F.P. J. Clin. Invest. (2004) [Pubmed]
  14. Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320. Demeter, L.M., Hughes, M.D., Coombs, R.W., Jackson, J.B., Grimes, J.M., Bosch, R.J., Fiscus, S.A., Spector, S.A., Squires, K.E., Fischl, M.A., Hammer, S.M. Ann. Intern. Med. (2001) [Pubmed]
  15. Mechanism of indinavir-induced hyperbilirubinemia. Zucker, S.D., Qin, X., Rouster, S.D., Yu, F., Green, R.M., Keshavan, P., Feinberg, J., Sherman, K.E. Proc. Natl. Acad. Sci. U.S.A. (2001) [Pubmed]
  16. Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults. McMahon, D., Lederman, M., Haas, D.W., Haubrich, R., Stanford, J., Cooney, E., Horton, J., Kelleher, D., Ross, L., Cutrell, A., Lee, D., Spreen, W., Mellors, J.W. Antivir. Ther. (Lond.) (2001) [Pubmed]
  17. Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection. Kaufmann, G.R., Zaunders, J.J., Cunningham, P., Kelleher, A.D., Grey, P., Smith, D., Carr, A., Cooper, D.A. AIDS (2000) [Pubmed]
  18. Short-term treatment with indinavir fails to reduce the glucose requirement in a patient with malignant insulinoma. Schütt, M., Aries, S.P., Rosenfeldt, M., Peters, A., Klein, H.H. Am. J. Med. (2000) [Pubmed]
  19. Indinavir concentrations and St John's wort. Piscitelli, S.C., Burstein, A.H., Chaitt, D., Alfaro, R.M., Falloon, J. Lancet (2000) [Pubmed]
  20. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Vacca, J.P., Dorsey, B.D., Schleif, W.A., Levin, R.B., McDaniel, S.L., Darke, P.L., Zugay, J., Quintero, J.C., Blahy, O.M., Roth, E. Proc. Natl. Acad. Sci. U.S.A. (1994) [Pubmed]
  21. Intracellular indinavir pharmacokinetics in HIV-infected patients: comparison with plasma pharmacokinetics. Hennessy, M., Clarke, S., Spiers, J.P., Mulcahy, F., Kelleher, D., Meadon, E., Maher, B., Bergin, C., Khoo, S., Tjia, J., Hoggard, P., Back, D., Barry, M. Antivir. Ther. (Lond.) (2003) [Pubmed]
  22. Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients. Boyd, M., Mootsikapun, P., Burger, D., Chuenyam, T., Ubolyam, S., Mahanontharit, A., Sangkote, J., Bunyaprawit, P., Horsakulchai, M., Lange, J., Cooper, D., Phanuphak, P., Ruxrungtham, K. Antivir. Ther. (Lond.) (2005) [Pubmed]
  23. Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytes. Janneh, O., Hoggard, P.G., Tjia, J.F., Jones, S.P., Khoo, S.H., Maher, B., Back, D.J., Pirmohamed, M. Antivir. Ther. (Lond.) (2003) [Pubmed]
  24. Indinavir in cerebrospinal fluid of HIV-1-infected patients. Ståhle, L., Martin, C., Svensson, J.O., Sönnerborg, A. Lancet (1997) [Pubmed]
  25. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Race, E.M., Adelson-Mitty, J., Kriegel, G.R., Barlam, T.F., Reimann, K.A., Letvin, N.L., Japour, A.J. Lancet (1998) [Pubmed]
  26. Visceral abdominal-fat accumulation associated with use of indinavir. Miller, K.D., Jones, E., Yanovski, J.A., Shankar, R., Feuerstein, I., Falloon, J. Lancet (1998) [Pubmed]
  27. Crystalluria and urinary tract abnormalities associated with indinavir. Kopp, J.B., Miller, K.D., Mican, J.A., Feuerstein, I.M., Vaughan, E., Baker, C., Pannell, L.K., Falloon, J. Ann. Intern. Med. (1997) [Pubmed]
  28. Ritonavir/saquinavir plus one nucleoside reverse transcriptase inhibitor (NRTI) versus indinavir plus two NRTIs in protease inhibitor-naive HIV-1-infected adults (IRIS study). Florence, E., Dreezen, C., Desmet, P., Smets, E., Fransen, K., Vandercam, B., Pelgrom, J., Clumeck, N., Colebunder, R. Antivir. Ther. (Lond.) (2001) [Pubmed]
  29. Drug resistance mutations in HIV-1-infected subjects during protease inhibitor-containing highly active antiretroviral therapy with nelfinavir or indinavir. Yerly, S., Rickenbach, M., Popescu, M., Taffe, P., Craig, C., Perrin, L. Antivir. Ther. (Lond.) (2001) [Pubmed]
  30. ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages. Jorajuria, S., Dereuddre-Bosquet, N., Becher, F., Martin, S., Porcheray, F., Garrigues, A., Mabondzo, A., Benech, H., Grassi, J., Orlowski, S., Dormont, D., Clayette, P. Antivir. Ther. (Lond.) (2004) [Pubmed]
  31. Select HIV protease inhibitors alter bone and fat metabolism ex vivo. Jain, R.G., Lenhard, J.M. J. Biol. Chem. (2002) [Pubmed]
  32. Indinavir induces acute and reversible peripheral insulin resistance in rats. Hruz, P.W., Murata, H., Qiu, H., Mueckler, M. Diabetes (2002) [Pubmed]
  33. Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. Caron, M., Auclair, M., Sterlingot, H., Kornprobst, M., Capeau, J. AIDS (2003) [Pubmed]
  34. Change in circulating levels of the chemokines macrophage inflammatory proteins 1 alpha and 11 beta, RANTES, monocyte chemotactic protein-1 and interleukin-16 following treatment of severely immunodeficient HIV-infected individuals with indinavir. Bisset, L.R., Rothen, M., Joller-Jemelka, H.I., Dubs, R.W., Grob, P.J., Opravil, M. AIDS (1997) [Pubmed]
  35. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. Huisman, M.T., Smit, J.W., Crommentuyn, K.M., Zelcer, N., Wiltshire, H.R., Beijnen, J.H., Schinkel, A.H. AIDS (2002) [Pubmed]
  36. Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes. Yong, W.P., Ramirez, J., Innocenti, F., Ratain, M.J. Clin. Cancer Res. (2005) [Pubmed]
  37. Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir. Boyd, M.A., Srasuebkul, P., Ruxrungtham, K., Mackenzie, P.I., Uchaipichat, V., Stek, M., Lange, J.M., Phanuphak, P., Cooper, D.A., Udomuksorn, W., Miners, J.O. Pharmacogenet. Genomics (2006) [Pubmed]
  38. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team). Descamps, D., Flandre, P., Calvez, V., Peytavin, G., Meiffredy, V., Collin, G., Delaugerre, C., Robert-Delmas, S., Bazin, B., Aboulker, J.P., Pialoux, G., Raffi, F., Brun-Vézinet, F. JAMA (2000) [Pubmed]
  39. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. Havlir, D.V., Hellmann, N.S., Petropoulos, C.J., Whitcomb, J.M., Collier, A.C., Hirsch, M.S., Tebas, P., Sommadossi, J.P., Richman, D.D. JAMA (2000) [Pubmed]
  40. Indinavir concentrations in hair from patients receiving highly active antiretroviral therapy. Bernard, L., Peytavin, G., Vuagnat, A., de Truchis, P., Perronne, C. Lancet (1998) [Pubmed]
WikiGenes - Universities